This is a preview of subscription content, log in via an institution to check access.
References
Puig L, López A, Vilarrasa E, García I. Efficacy of biologics in the treatment of moderate–to–severe plaque psoriasis: a systematic review and meta–analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol 2014; 28: 1633–53.
de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808–14.
Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long–term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015; 172: 244–52.
Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Derma tologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632–40.
Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease–based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol 2016; 30: 1148–58.
Zweegers J, Groenewoud JMM, van den Reek JMPA, et al. Comparison of the 1–and 5–year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol 2017; 176: 1001–9.
Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate–to–severe plaque psoriasis. Br J Dermatol 2018; 178: 509–19.
Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis. JAMA Dermatol 2015; 151: 961–9.
Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real–world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol 2016; 74: 851–61.e4.
Zhang M, Brenneman S, Carter C, et al. Patient–reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence 2015; 16: 777–84.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Torres, T., Filipe, P., Basto, A.S. et al. The DRAGON study: biologic DRug survivAl in PortuGuese psOriasis patieNts. Eur J Dermatol 28, 685–687 (2018). https://doi.org/10.1684/ejd.2018.3353
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2018.3353